Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $186 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) following today's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE